Pulmonx Corp. (LUNG)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$2.21-2.21%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · LUNG
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -77.0% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 9.3% |
Growth built into the price is above our model estimate.
The price assumes 86.2 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 87 industry peers · Company calendar date is not available
LUNG — earnings in line
Dated 2026-04-29
Results of Operations and Financial Condition. On April 29, 2026, Pulmonx Corporation (the “Company”) issued a press release announcing its financial results for the first fiscal quarter ended March 31, 2026. A copy of the Company’s press release dated April 29, 2026, titled “Pulmonx Reports First Quarter 2026 Financial Results” is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information (including the exhibit hereto) is being furnished under “
Why it matters: This would signal a recovery in sales after the recent declines. It is crucial to meet the annual revenue guidance of $90M to $92M.
Supportive ifQ2 revenue growth is over 10% compared to last year. This shows a recovery.
Worry ifQ2 revenue growth is below 0%. This shows sales are still declining.
Why it matters: A gross margin above 75% shows strong cost control and pricing power.
Supportive ifGross margin reported above 75% for the next quarter.
Worry ifGross margin falls below 75% in the next quarter.
Why it matters: Growth outside China shows demand for products. This growth helps the company's plans.
Supportive ifInternational revenue outside China grows more than 10% each year.
Worry ifInternational revenue outside China falls or grows less than 10% each year.
Why it matters: Positive U.S. revenue growth would signal success in management's strategy to drive revenue.
Supportive ifU.S. revenue shows year-over-year growth of at least 1% in the next quarter.
Worry ifU.S. revenue continues to decline year-over-year for another quarter.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$274 on $10,000 · ±2.7% | How much price usually moves either way. |
| Bad day | $678 loss on $10,000 · 6.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,500 loss on $10,000 · 55.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Watching cash levels helps check financial health. A drop matches management's plans.
Watch forCash and cash equivalents drop by about $23 million for the full year 2026.
Also watch forCash and cash equivalents decrease by less than $20 million for the full year 2026.
Why it matters: U.S. revenue has fallen for two quarters. A return to growth signals recovery in the core market.
Supportive ifU.S. revenue grows year over year in Q3 2026, surpassing $14.2 million.
Worry ifU.S. revenue continues to decline year over year in Q3 2026.
Why it matters: Keeping expenses on track shows good cost control. This helps the company make money.
Supportive ifTotal operating expenses fall within the range of $109 million to $111 million for 2026.
Worry ifTotal operating expenses go over $111 million for the full year 2026.
Why it matters: Keeping a gross margin around this level helps the company make money and work well.
Supportive ifGross margin for 2026 remains close to the guided 76% in Q3 2026.
Worry ifGross margin drops below 75% in Q3 2026.
Why it matters: Meeting revenue guidance is crucial for Pulmonx to show it can grow. This affects investor confidence.
Supportive ifQ2 revenue reported at least $22.5M, on track for $90M to $92M annual guidance.
Worry ifQ2 revenue was below $22.5M. This shows challenges in meeting annual goals.
Why it matters: The earnings report will show if revenue growth is improving or still slowing. Investors will focus on this.
Watch forThe earnings report shows revenue growth speeding up. It is now above 10% year over year.
Also watch forEarnings report shows revenue growth below 5% year over year.